Do's and Dont's Developed for Direct Oral Anticoagulants

ReachMD Healthcare Image


Central Illustration. Credit: Journal of the American College of Cardiology (2024). DOI: 10.1016/j.jacc.2023.10.038

Direct oral anticoagulants (DOACs) are a common treatment for patients with a wide variety of cardiovascular conditions. DOACs are the preferred treatment over vitamin K antagonists (VKAs) for many patients with atrial fibrillation or venous thromboembolism since the latter would have a higher risk of intracranial bleeding and a more complex dosing routine. However, new research suggests that DOACs should not be the first line of treatment for every patient who needs to treat or prevent blood clots.

A systematic overview from researchers at Brigham and Women's Hospital, a founding member of Mass General Brigham, discusses the efficacy of DOACs compared to other treatment methods. This review utilized data from randomized controlled trials to compare DOACs with other treatment methods for various cardiovascular conditions.

Although there is merit to using DOACs in many common conditions, the manuscript provides a robust summary of clinical trials indicating that DOACs fare worse in patients with mechanical heart valves, thrombotic antiphospholipid syndrome, atrial fibrillation associated with rheumatic heart disease, and patients with embolic stroke of unclear source. The authors also highlight clinical scenarios in which there is uncertainty, with a look toward the future for better evidence generation.

"The results we reviewed here have significant implications for optimizing anticoagulation therapy and improving patient outcomes in clinical practice," said Behnood Bikdeli, MD, MS, of the Brigham's Heart and Vascular Center. "There is a critical need for further research regarding why DOACs are less efficacious or safe than the standard of care in certain scenarios."

The paper is published in the Journal of the American College of Cardiology.

More information: Antoine Bejjani et al, When Direct Oral Anticoagulants Should Not Be Standard Treatment, Journal of the American College of Cardiology (2024). DOI: 10.1016/j.jacc.2023.10.038

Citation: Dos and don'ts developed for direct oral anticoagulants (2024, February 23) retrieved 23 February 2024 from

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Facebook Comments


We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free